The US National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), has awarded a Small Business Initiative Research (SBIR) grant of approximately $278,000 to Aradigm to study the use of Aradigm’s Pulmaquin and Lipoquin inhaled liposomal ciprofloxacin products for the treatment of pulmonary non-tuberculous mycobacteria (NTM) infections.
Aradigm President and CEO Igor Gonda commented, “I am very pleased that the National Institutes of Health recognized the potential of our therapeutic approach to become an effective tool to help patients with PNTM infections, a severe chronic respiratory condition that is a growing concern in the US and other countries. . . . We already have a substantial amount of safety information in animal models and humans, as well as efficacy in other infections for Pulmaquin and Lipoquin. This one-year consortium program is an essential prerequisite for entry into advanced human clinical trials in patients with PNTM.”
Read the Aradigm press release.
